https://mivision.com.au/2026/02/spanish-trial-confirms-rlrl-plus-ok-slow-myopia-progression/

Spanish Trial Confirms RLRL Plus OK Slow Myopia Progression

A landmark Spanish study1 has provided the strongest evidence to date of the efficacy of repeated low-level red-light (RLRL) in European children, and that its combination with orthokeratology (OK), in particular, offers substantially greater myopia control than OK alone. Published in the British Journal of Ophthalmology, the 12-month randomised controlled trial is the first fully Caucasian and European study of RLRL to be published, reinforcing findings of RLRL and OK combination therapy previously demonstrated only in East Asian populations.

The study was conducted at the Fernández-Velázquez Centre in Madrid and supported by devices from Eyerising International. It recruited 26 Caucasian Spanish children aged 10–13 years with myopia, randomly allocating them either to a RLRL plus OK group (RCO) or an OK group. The trial was a single-site, randomised, parallel-group, and non-blinded, with assessments performed at baseline and at six, nine, and 12 months. Children in the RCO group also underwent additional assessments at one and three months.

Significantly Slower Myopia Progression

Axial length (AL) change was the primary outcome, analysed using a longitudinal mixed model. At 12 months, the adjusted mean axial length change was -0.124 mm (95% CI -0.164 to -0.084) in the combination RCO group, representing significant axial shortening, while children wearing OK lenses alone showed continued eye growth of 0.102 mm (95% CI 0.068 to 0.136). This amounted to an adjusted mean difference of -0.226 mm (p < 0.001) between the groups. In practical terms, the combination therapy slowed axial elongation by approximately 0.215–0.226 mm more than OK alone over one year.

These findings mirror the results of previous East Asian studies, where RLRL has been shown to significantly reduce axial elongation, both independently and when combined with OK. In comparison, two studies in East Asia recruited poor responders to OK with continued myopia progression while on OK alone for one year, who were then randomised to either receive combination RCO or remain on OK alone. This Spanish study instead recruited treatment-naïve patients to begin RCO or OK. Similarly, all three studies reported axial shortening in the RCO group, an increasingly recognised phenomenon achieved with RLRL therapy. More than 80% of children in the RCO group achieved AL shortening greater than 0.05 mm, sustained to 12 months. No participants in the OK group exhibited any shortening.

Purchase Eyepower Red at https://www.eye-power.co.uk/?aff=22 

Safety and Tolerability

Safety outcomes were equally encouraging in this study. The adjusted mean change in macular thickness (MT), the study’s secondary endpoint, showed no significant differences between the two groups over the 12-month period. Optical coherence tomography (OCT) imaging revealed no structural concerns and no adverse events were reported.

Safety outcomes were equally encouraging in this study.

Treatment adherence was high, with a median compliance of 71% in the RLRL group. Interestingly, this was consistent with previously published RLRL trials in East Asia, demonstrating a similar adherence profile in Caucasian populations.

Broader Implications for Europe

The study holds significance for Western practitioners, as almost all published RLRL clinical data to date has involved East Asian children. Although RLRL therapy has now been available with strong real-world results thus far reported in other Western countries (e.g. Australia, New Zealand, United Kingdom, Norway), this would be the first 12-month study published demonstrating Caucasian treatment effect.

“This study demonstrated the synergistic effect of RLRL on OK in a European population, for which data had been limited,” the authors wrote. “Despite the satisfactory efficacy of OK in this cohort, adding RLRL therapy provided a significantly greater myopia control effect and slowed axial elongation by more than 0.2 mm annually compared to OK monotherapy, potentially lowering the long-term risk of vision-threatening complications such as myopic maculopathy.”

The researchers said the findings suggest that the biological mechanisms underpinning RLRL’s effect are not population-specific. “RLRL therapy with OK is an effective and safe myopia control strategy in Caucasian Spanish children,” the authors concluded, “supporting the potential generalisability of the synergistic effect across diverse ethnic groups.”

While the results are strong, the authors highlight that the study’s small sample size warrants larger, multi-centre trials across different European and multi-ethnic populations. Such studies would help clarify the consistency of treatment response, long-term durability of axial shortening, and the optimal integration of RLRL into European clinical pathways.

Reference

1. Fernández Fidalgo MJ, Ferigo Ferrel VD, Wu Y, et al. Repeated low-level red-light therapy combined with orthokeratology for myopia control in Spain: a randomised controlled study. British Journal of Ophthalmology Published Online First: 20 November 2025. doi: 10.1136/bjo-2025-328347.

Growing Evidence for Safety/Efficacy of RLRL

A new three-year study is strengthening the case for repeated low-level red light (RLRL) therapy in myopia management, with researchers reporting sustained effectiveness alongside strong safety outcomes.

Adding further weight to the findings is independent analysis on the Eyerising Myopia Management Device from a world-leading authority in ophthalmic laser, Emeritus Professor John Marshall, from University College London.

Published in the British Journal of Ophthalmology,1 the multicentre real-world study of RLRL for myopia control followed 362 children and adolescents with myopia, including a cohort treated with RLRL for at least three years.

Until recently, most published studies reported follow-up duration of up to two years. A key question for clinicians has, therefore, been whether the benefits and safety of this therapy can be sustained over longer periods, as myopia typically requires multi-year treatment.

The authors of this latest study found that after three years, more than 72% of patients achieved controlled myopia progression, defined as minimal axial elongation, while average axial length growth remained low. The therapy also demonstrated even higher control rates over shorter treatment durations.

Crucially, safety findings were equally reassuring. Best-corrected visual acuity was maintained in all patients. Full-field electroretinography showed no treatment duration-dependent differences, suggesting no severe adverse events, even after three years of therapy.

https://mivision.com.au/2026/04/growing-evidence-for-safety-efficacy-of-rlrl/

Although scientific studies have shown promising results from PBM Red light therapy, results will vary by individual.  The goal of red light therapy is meant to help slow down the progression of Dry AMD Macular Degeneration, improvement of vision is not guaranteed.  The use of red light therapy at home as a wellness device DOES NOT replace routine examinations & treatments by your eye doctor plus the need for daily balanced nutrient-dense diet, outdoor light exposure, rest/exercise, & lifestyle changes.